We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
C-reactive protein levels and treatment resistance in schizophrenia-A Danish population-based cohort study.
- Authors
Horsdal, Henriette Thisted; Wimberley, Theresa; Benros, Michael Eriksen; Gasse, Christiane
- Abstract
Objective Schizophrenia is associated with increased levels of inflammatory markers. However, it remains unclear whether inflammatory markers are associated with treatment-resistant schizophrenia. Methods We conducted a population-based follow-up study among individuals with a first-time schizophrenia diagnosis and a baseline C-reactive protein measurement (a commonly available marker of systemic inflammation) from 2000 to 2012. We defined treatment resistance as the earliest observed instance of either clozapine initiation or hospital admission due to schizophrenia after having received at least 2 prior antipsychotic monotherapy trials of adequate duration. We used adjusted Cox regression analysis to calculate hazard ratios. Results We identified 390 individuals with a C-reactive protein measurement at first-time schizophrenia diagnosis. A nonsignificant higher median C-reactive protein (4.0 vs. 3.1 mg/L, p = .13) was observed among the 52 (13.3%) treatment-resistant individuals. Increased levels of C-reactive protein (above 3 mg/L) at baseline were not associated with treatment resistance (adjusted hazard ratio = 0.99, 95% confidence interval [0.56, 1.73]). Conclusions C-reactive protein, as a single inflammatory marker, appears insufficient to detect treatment-resistant schizophrenia.
- Subjects
SCHIZOPHRENIA treatment; DIAGNOSIS of schizophrenia; C-reactive protein; CLOZAPINE; INFLAMMATION
- Publication
Human Psychopharmacology: Clinical & Experimental, 2017, Vol 32, Issue 6, pn/a
- ISSN
0885-6222
- Publication type
Article
- DOI
10.1002/hup.2632